Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
2 minute read

Cartesian Therapeutics’ Rare Disease Candidate Shows Long Lasting Benefit Over Argenx’s Vyvgart, Analyst Initiates With Buy

By Vandana Singh
April 10, 2:34 PM
Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current standards. Analysts project substantial market capture and peak sales potential.

ARGX

Read More
2 minute read

Cartesian Therapeutics Announces Approval Of Conversion Of Series A Convertible Preferred Stock And Plans To Effect 1-For-30 Reverse Stock Split Effective After The Closing Of Trading Hours On April 4, 2024

By Benzinga Newsdesk
March 28, 4:16 PM
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced results from a special meeting of stockholders held

RNAC